Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib.

Unlabelled: Early assessment of response at 3 months of tyrosine kinase inhibitor treatment has become an important tool to predict favorable outcome. We sought to investigate the impact of relative changes of BCR-ABL transcript levels within the initial 3 months of therapy. In order to achieve accu...

Descripción completa

Detalles Bibliográficos

Publicado en:	Leukemia (08876924) Vol. 28; no. 10; pp. 1988 - 1993
Autores principales:	Hanfstein, B, Shlyakhto, V, Lauseker, M, Hehlmann, R, Saussele, S, Dietz, C, Erben, P, Fabarius, A, Proetel, U, Schnittger, S, Krause, S W, Schubert, J, Einsele, H, Hänel, M, Dengler, J, Falge, C, Kanz, L, Neubauer, A, Kneba, M, Stegelmann, F
Formato:	research randomized controlled trial Journal Article
Publicado:	Springer Nature Oct2014
Acceso en línea:	Ver este registro en EBSCOhost